Sickle cell disease affects more Africans than any other genetic condition, yet ...
Africa Trials
9
US Trials
574
Gap Ratio
64x
Nations
54
Key Finding
Africa hosted 9 sickle cell disease trials versus 574 in the United States, a 64-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Sickle cell disease affects more Africans than any other genetic condition, yet trial investment is a fraction of what cystic fibrosis receives in the US, reflecting whose diseases get funded.
The Evidence 137 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of sickle cell disease trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 9 sickle cell disease trials (0.0% of its portfolio) compared to 574 in the United States, yielding a 0.0-fold disparity in per-population investment. The Theil index of 1.288 confirmed between-country inequality, with decomposition showing most disparity arising from inter-regional gaps. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of sickle cell disease trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 9 sickle cell disease trials (0.
Interpretation
0% of its portfolio) compared to 574 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
The Theil index of 1.
Extra
288 confirmed between-country inequality, with decomposition showing most disparity arising from inter-regional gaps.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is limited by reliance on ClinicalTrials.
Extra
gov alone, which may undercount locally registered African studies.